Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients

JM. Hartinger, P. Ryšánek, O. Slanař, M. Šíma

. 2022 ; 47 (9) : 1362-1367. [pub] 20220807

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024601

Grantová podpora
Cooperatio project (research area PHAR) Univerzita Karlova v Praze
SVV 260523 Univerzita Karlova v Praze

WHAT IS KNOWN AND OBJECTIVES: mTOR inhibitors possess narrow therapeutic range and substantial pharmacokinetic variability and the consequences from suboptimal dosing are serious. The aim of this review is to summarize the current knowledge about the factors influencing mTOR inhibitors pharmacokinetics and the possibility of using these relationships in order to improve its therapy individualization in solid organ transplanted patients. METHODS: Literature search from Pubmed and Web of Science databases were performed using Boolean search operators in order to identify relevant studies. RESULTS AND DISCUSSION: A total of 701 reports were identified from the initial literature search. Out of which 40 studies dealt with relationships between various factors and pharmacokinetics of mTOR inhibitors and with relevance of these associations for dosage optimization. WHAT IS NEW AND CONCLUSION: The overview of the current covariates for pharmacokinetic variability of mTOR inhibitors has been provided on the level of absorption, distribution and elimination, and consequences of these relationships for dosing optimization has been summarized.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024601
003      
CZ-PrNML
005      
20240522101900.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jcpt.13753 $2 doi
035    __
$a (PubMed)35934622
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hartinger, Jan $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague 2, Czech Republic $7 xx0224709
245    10
$a Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients / $c JM. Hartinger, P. Ryšánek, O. Slanař, M. Šíma
520    9_
$a WHAT IS KNOWN AND OBJECTIVES: mTOR inhibitors possess narrow therapeutic range and substantial pharmacokinetic variability and the consequences from suboptimal dosing are serious. The aim of this review is to summarize the current knowledge about the factors influencing mTOR inhibitors pharmacokinetics and the possibility of using these relationships in order to improve its therapy individualization in solid organ transplanted patients. METHODS: Literature search from Pubmed and Web of Science databases were performed using Boolean search operators in order to identify relevant studies. RESULTS AND DISCUSSION: A total of 701 reports were identified from the initial literature search. Out of which 40 studies dealt with relationships between various factors and pharmacokinetics of mTOR inhibitors and with relevance of these associations for dosage optimization. WHAT IS NEW AND CONCLUSION: The overview of the current covariates for pharmacokinetic variability of mTOR inhibitors has been provided on the level of absorption, distribution and elimination, and consequences of these relationships for dosing optimization has been summarized.
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $7 D007166
650    _2
$a mTOR inhibitory $7 D000091203
650    12
$a transplantace orgánů $7 D016377
650    12
$a sirolimus $x farmakokinetika $x terapeutické užití $7 D020123
650    _2
$a TOR serin-threoninkinasy $7 D058570
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Ryšánek, Pavel $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague 2, Czech Republic
700    1_
$a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague 2, Czech Republic
700    1_
$a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague 2, Czech Republic $1 https://orcid.org/https://orcid.org/000000026541738X
773    0_
$w MED00007277 $t Journal of clinical pharmacy and therapeutics $x 1365-2710 $g Roč. 47, č. 9 (2022), s. 1362-1367
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35934622 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20240522101856 $b ABA008
999    __
$a ok $b bmc $g 1854367 $s 1175891
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 47 $c 9 $d 1362-1367 $e 20220807 $i 1365-2710 $m Journal of clinical pharmacy and therapeutics $n J Clin Pharm Ther $x MED00007277
GRA    __
$a Cooperatio project (research area PHAR) $p Univerzita Karlova v Praze
GRA    __
$a SVV 260523 $p Univerzita Karlova v Praze
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...